Namita Sood, MD
Pulmonary Disease · Sacramento, CANPI 1770697542
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Boehringer Ingelheim at 34.6% of the total. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $795.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$78K
- Bayer$56K
- United Therapeutics Corporation$53K
- Merck$28K
- Actelion Pharmaceuticals US, Inc.$8K
- Pfizer$2K
- plus $2K from 6 others
Across 166 payments — averaging $20,739 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.6M
- United Therapeutics Corporation$1M
- Roche Products Limited$439K
- Sumitomo Pharma America, Inc.$254K
- Janssen Research & Development, LLC$58K
- Boehringer Ingelheim$55K
- plus $7K from 2 others
What the payments were for
- Consulting fees$89,43639%
- Speaking & faculty fees$104,24146%
- Travel & lodging$22,12410%
- Food & beverage$11,0095%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 54 | $78,453 |
| Bayer | 52 | $56,292 |
| United Therapeutics Corporation | 101 | $52,738 |
| Merck | 39 | $27,606 |
| Actelion Pharmaceuticals US, Inc. | 24 | $8,426 |
| Pfizer | 5 | $1,782 |
| Lupin Inc. | 1 | $1,000 |
| AbbVie | 2 | $250 |
| Sandoz | 4 | $124 |
| Covis Pharma GmbH | 1 | $86 |
| Gilead | 1 | $32 |
| Insmed, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$226,812 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 305 | $3,881,949 |
| AdempasRiociguat | 187 | $2,502,085 |
| UptraviSelexipag | 61 | $1,218,722 |
| Ambrisentan | 360 | $1,217,722 |
| Tyvaso DpiTreprostinil | 38 | $912,635 |
| OpsumitMacitentan | 73 | $884,304 |
| LetairisAmbrisentan | 56 | $819,405 |
| Orenitram ErTreprostinil Diolamine | 34 | $172,343 |
| AdcircaTadalafil | 29 | $149,611 |
| Pirfenidone | 110 | $112,472 |
| Tadalafil | 184 | $71,481 |
| Mycophenolate Mofetil | 169 | $26,784 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $22,438 |
| EliquisApixaban | 21 | $20,523 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $18,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $78,453 | $3,917,889363 claims |
| BayerAdempas | $56,292 | $2,502,085187 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $8,426 | $2,103,026134 claims |
| GileadLetairis | $32 | $819,40556 claims |
| United Therapeutics CorporationAdcirca | $52,738 | $149,61129 claims |
| PfizerEliquis | $1,782 | $20,52321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Sacramento
- Samuel LouieSacramento$2.8M
- Brooks KuhnSacramento$188K
- Amir ZekiSacramento$149K
- Mark AvdalovicSacramento$79K
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.